ReoPro GPIIb/IIIa inhibitor of platelet aggregation data

Follow-up results of the Phase III EPIC trial of ReoPro were published in the Journal of the American Medical Association, showing an improved outcome at three years.

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE